share_log

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $28

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $28

Oppenheimer维持对evolent health的Outperform评级,将价格目标下调至28美元
Benzinga ·  2024/11/18 08:59  · 评级/大行评级

Oppenheimer analyst Jeff Jones maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $34 to $28.

奥本海默分析师杰夫·琼斯维持Evolent Health(纽约证券交易所代码:EVH)的跑赢大盘,并将目标股价从34美元下调至28美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发